309 related articles for article (PubMed ID: 23842190)
1. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
Alachkar N; Wei C; Arend LJ; Jackson AM; Racusen LC; Fornoni A; Burke G; Rabb H; Kakkad K; Reiser J; Estrella MM
Transplantation; 2013 Oct; 96(7):649-56. PubMed ID: 23842190
[TBL] [Abstract][Full Text] [Related]
2. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.
Alachkar N; Li J; Matar D; Vujjini V; Alasfar S; Tracy M; Reiser J; Wei C
BMC Nephrol; 2018 Dec; 19(1):361. PubMed ID: 30558559
[TBL] [Abstract][Full Text] [Related]
3. Podocyte foot process effacement in postreperfusion allograft biopsies correlates with early recurrence of proteinuria in focal segmental glomerulosclerosis.
Chang JW; Pardo V; Sageshima J; Chen L; Tsai HL; Reiser J; Wei C; Ciancio G; Burke GW; Fornoni A
Transplantation; 2012 Jun; 93(12):1238-44. PubMed ID: 22499148
[TBL] [Abstract][Full Text] [Related]
4. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
Staeck O; Slowinski T; Lieker I; Wu K; Rudolph B; Schmidt D; Brakemeier S; Neumayer HH; Wei C; Reiser J; Budde K; Halleck F; Khadzhynov D
Transplantation; 2015 Dec; 99(12):2593-7. PubMed ID: 26371597
[TBL] [Abstract][Full Text] [Related]
5. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
Wei C; El Hindi S; Li J; Fornoni A; Goes N; Sageshima J; Maiguel D; Karumanchi SA; Yap HK; Saleem M; Zhang Q; Nikolic B; Chaudhuri A; Daftarian P; Salido E; Torres A; Salifu M; Sarwal MM; Schaefer F; Morath C; Schwenger V; Zeier M; Gupta V; Roth D; Rastaldi MP; Burke G; Ruiz P; Reiser J
Nat Med; 2011 Jul; 17(8):952-60. PubMed ID: 21804539
[TBL] [Abstract][Full Text] [Related]
6. Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.
Jin J; Li YW; He Q
Transplant Proc; 2015; 47(6):1760-5. PubMed ID: 26293047
[TBL] [Abstract][Full Text] [Related]
7. Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.
Morath C; Wei C; Macher-Goeppinger S; Schwenger V; Zeier M; Reiser J
Am J Ther; 2013; 20(2):226-9. PubMed ID: 23466622
[TBL] [Abstract][Full Text] [Related]
8. Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.
Harel E; Shoji J; Abraham V; Miller L; Laszik ZG; King A; Dobi D; Szabo G; Hann B; Sarwal MM; Craik CS; Vincenti F
Transplantation; 2020 Jan; 104(1):54-60. PubMed ID: 31449183
[TBL] [Abstract][Full Text] [Related]
9. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.
Sinha A; Bajpai J; Saini S; Bhatia D; Gupta A; Puraswani M; Dinda AK; Agarwal SK; Sopory S; Pandey RM; Hari P; Bagga A
Kidney Int; 2014 Mar; 85(3):649-58. PubMed ID: 24429405
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.
Winnicki W; Sunder-Plassmann G; Sengölge G; Handisurya A; Herkner H; Kornauth C; Bielesz B; Wagner L; Kikić Ž; Pajenda S; Reiter T; Schairer B; Schmidt A
Sci Rep; 2019 Sep; 9(1):13783. PubMed ID: 31551522
[TBL] [Abstract][Full Text] [Related]
11. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report.
Bock ME; Price HE; Gallon L; Langman CB
Clin J Am Soc Nephrol; 2013 Aug; 8(8):1304-11. PubMed ID: 23620441
[TBL] [Abstract][Full Text] [Related]
12. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.
Franco Palacios CR; Lieske JC; Wadei HM; Rule AD; Fervenza FC; Voskoboev N; Garovic VD; Zand L; Stegall MD; Cosio FG; Amer H
Transplantation; 2013 Aug; 96(4):394-9. PubMed ID: 23736353
[TBL] [Abstract][Full Text] [Related]
13. Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
Harel E; Shoji J; Abraham V; Miller L; Laszik Z; Thurison T; King A; Olshen A; Leung J; Szabo G; Hann B; Høyer-Hansen G; Craik CS; Vincenti F
Clin Transplant; 2019 Mar; 33(3):e13487. PubMed ID: 30689221
[TBL] [Abstract][Full Text] [Related]
14. Update on Recurrent Focal Segmental Glomerulosclerosis in Kidney Transplantation.
Shoji J; Mii A; Terasaki M; Shimizu A
Nephron; 2020; 144 Suppl 1():65-70. PubMed ID: 33260184
[TBL] [Abstract][Full Text] [Related]
15. Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.
Li F; Zheng C; Zhong Y; Zeng C; Xu F; Yin R; Jiang Q; Zhou M; Liu Z
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1903-11. PubMed ID: 25318750
[TBL] [Abstract][Full Text] [Related]
16. Focal segmental glomerular sclerosis recurrence with massive proteinuria and anuria immediately after kidney transplantation.
Maruyama M; Kitamura H; Akutsu N; Otsuki K; Hasegawa M; Aoyama H; Matsumoto I; Saigo K; Asano T
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():93-5. PubMed ID: 26031597
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte β3 Integrin.
Hladunewich MA; Cattran D; Sethi SM; Hayek SS; Li J; Wei C; Mullin SI; Reich HN; Reiser J; Fervenza FC
Kidney Int Rep; 2022 Jan; 7(1):68-77. PubMed ID: 35005315
[TBL] [Abstract][Full Text] [Related]
18. Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis.
Harita Y; Ishizuka K; Tanego A; Sugawara N; Chikamoto H; Akioka Y; Tsurumi H; Miura K; Gotoh Y; Tsujita M; Yamamoto T; Horike K; Takeda A; Oka A; Igarashi T; Hattori M
Pediatr Nephrol; 2014 Sep; 29(9):1553-60. PubMed ID: 24705794
[TBL] [Abstract][Full Text] [Related]
19. suPAR and chronic kidney disease-a podocyte story.
Zeier M; Reiser J
Pflugers Arch; 2017 Aug; 469(7-8):1017-1020. PubMed ID: 28689240
[TBL] [Abstract][Full Text] [Related]
20. Serum suPAR in patients with FSGS: trash or treasure?
Maas RJ; Deegens JK; Wetzels JF
Pediatr Nephrol; 2013 Jul; 28(7):1041-8. PubMed ID: 23515666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
